> ## Content Index
> Fetch the complete content index at: https://www.fdaweb.com/llms.txt
> Use this file to discover other available public pages before exploring further.

# Lupin Says it Corrected GMP Issues at Indian Drug Plant
- URL: https://www.fdaweb.com/lupin-says-it-corrected-gmp-issues-at-indian-drug-plant/
- Published: 2016-11-04T12:00:00.000Z
- Updated: 2026-09-14T21:45:18.000Z
- Author: David McFarland
- Tags: Drugs, #legacy-id-D5137265

Lupin says it has resolved GMP deficiencies cited by FDA during an inspection in March at its Goa, India manufacturing plant. The agency issued a nine-item Form-483 related to “inadequacy and adherence to SOPs,” the company said after the inspection. The Goa facility manufactures a range of finished products for the U.S. market including oral and injectable drugs. In 2015, the agency issued a six-observation Form-483 after it audited Lupin’s Pithampur in Madhya Pradesh drug manufacturing facility. The plant reportedly produces both oral contraceptives and ophthalmic treatments for the U.S. market.